佛慈制药：2025年10月投资2,000万元参股科近泰基，布局放射性同位素药物赛道

Group 1 - The core viewpoint of the article is that the company, 佛慈制药, is making a strategic investment in 科近泰基新技术有限公司 to enhance its position in the radioactive isotope pharmaceutical sector [1] - The company plans to invest 20 million yuan by October 2025 to participate in the capital increase of 科近泰基, which is a wholly-owned subsidiary of the Chinese Academy of Sciences [1] - The main business of 科近泰基 includes the production, sales, operation, and collaborative research and development of medical isotopes such as α-radioactive isotopes 225Ac and 223Ra [1] Group 2 - This investment aims to seize opportunities in the precision radiotherapy industry and strengthen the company's innovation drive [1] - The move is expected to inject new momentum into the company's long-term development [1]